AstraZeneca To Reclaim Full Rights To Several Drugs From Merck For $647M
This article was originally published in The Pink Sheet Daily
Executive Summary
By exercising its option, AstraZeneca also positions itself to regain full rights to Nexium and Prilosec as early as 2012.